Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
GlobeNewswire, Inc.
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...
U.S. Ski & Snowboard Names Dr. Thomas R. Hackett Chief Medical Officer
GlobeNewswire, Inc.
Vail, CO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- U.S. Ski & Snowboard has announced the promotion of Thomas R. Hackett, M.D., to Chief Medical Officer (CMO). Dr. Hackett, a complex knee and shoulder surgeon at The Steadman Clinic and sports medicine...
CJ Biomaterials Secures BPI, TÜV AUSTRIA Certifications for New PHACT™ All-PHA Compound Designed for Home Compostable Cutlery
GlobeNewswire, Inc.
PHACT™ CB0104A earned BPI Commercial and Home Compostable, TÜV AUSTRIA OK compost HOME & OK compost INDUSTRIAL Certifications New all-PHA compound is designed for cutlery, caps, enclosures, beauty packaging, and agriculture, and horticulture...
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
GlobeNewswire, Inc.
LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its...
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
GlobeNewswire, Inc.
In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients Denifanstat showed progressive and sustained improvements across all efficacy...
Navigator Medicines Presents New Data at EADV 2026 as Bispecific Antibody Program Advances at Speed in Hidradenitis Suppurativa
GlobeNewswire, Inc.
Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS) Recruiting Ahead of Schedule Early Cohorts in Phase 1 Study of Next-Generation Subcutaneous Bispecific Antibody NAV-242 Indicate Extended Half Life (HLE) on Path to Goal of...
Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
GlobeNewswire, Inc.
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts.
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
GlobeNewswire, Inc.
Ad hoc announcement pursuant to Art. 53 LR. A conference call will be held on September 30, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Strong momentum and expanding global access position AGAMREE® for...
Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
GlobeNewswire, Inc.
The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development The milestone triggers a payment to...
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
GlobeNewswire, Inc.
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
GlobeNewswire, Inc.
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need,...
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference
GlobeNewswire, Inc.
LAS VEGAS, NEVADA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), together with joint venture partner Austrianova, today announced that Prof. Walter H. Günzburg presented the companies’ encapsulated-cell...
Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic
GlobeNewswire, Inc.
Dr. Nora Dimon, VP of Clinical Development, to present preclinical findings on the Company’s lead retinal program, CoTx-101, including non-human primate data Rodolphe Clerval, CEO, to deliver a corporate presentation at the Euretina Innovation...
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
GlobeNewswire, Inc.
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Governor Meyer Signs Legislation Renaming Delaware Hospital in Honor of Eleanor Cain
Office of the Governor Delaware
FOR IMMEDIATE RELEASE Thursday, September 17, 2026 Media Contact: Jonah Anderson jonah.anderson@delaware.gov SMYRNA, Del. — Joined by state leaders, residents, staff, and members of the Cain family, Governor Matt Meyer today signed legislation...
Cooling Solutions For Medical Equipment Market Forecast Report Featuring Segment Analysis And Strategic Industry Insight
EIN Presswire
The Business Research Company's Cooling Solutions For Medical Equipment Market Forecast Report Featuring Segment Analysis And Strategic Industry Insight LONDON, GREATER LONDON, UNITED KINGDOM, September 16, 2026 /EINPresswire.com/ -- "The demand...
United Cerebral Palsy Announces 2026 Research Grant Awardees Advancing Innovation in Cerebral Palsy Care
EIN Presswire
Three projects will receive funding to advance clinical and translational research, improve care, and address gaps in diagnosis, treatment, and healthcare.
AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026
GlobeNewswire, Inc.
MILAN, Sept. 16, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its proprietary dual-AAV technology, today announced...
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
GlobeNewswire, Inc.
PARIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, will be presenting the...
FROM JANE FONDA TO PRINCESS CHARLÈNE: MAKE‐UP ARTIST KARIM SATTAR JOINS MEDICAL BEAUTY RESEARCH
EIN Presswire
Make-up artist and skincare expert Karim Sattar joins MBR to lead creative artistry, celebrity relations and global brand visibility.
Sign up for:
Austria Health Focus
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.